mRNA COVID-19 vaccine safety in patients with previous immediate hypersensitivity to pegaspargase

Affiliations

• ¹ Division of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tenn.
• ² Department of Pediatrics, Baylor College of Medicine, Houston, Texas; Section of Immunology, Allergy and Retrovirology, Texas Children's Hospital, Houston, Texas; William T. Shearer Center for Human Immunobiology, Texas Children's Hospital, Houston, Texas.
• ³ Division of Hematology and Oncology, Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tenn; Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tenn.
• ⁴ Division of Hematology and Oncology, Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tenn.
• ⁵ Pharmaceutical Services, Vanderbilt University Medical Center, Nashville, Tenn.
• ⁶ Department of Pediatric Pharmacy, Pharmacology, Monroe Carell, Jr. Children's Hospital at Vanderbilt, Nashville, Tenn.
• ⁷ Division of Infectious Diseases, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tenn; Department of Pathology, Microbiology and Immunology, Vanderbilt University School of Medicine, Nashville, Tenn; Institute for Immunology & Infectious Diseases, Murdoch University, Murdoch, WA, Australia.
• ⁸ Division of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tenn. Electronic address: [email protected].